News – Page 451 – Endpoints News

As lead drug flopped and AbbVie collab dissolved, cancer biotech resorts to buying rare disease company

3 years ago

Novo Nordisk joins Novartis, Roche in NLRP3 arena, betting $70M cash on NASH, cardiometabolic uses

3 years ago

I’m headed to London soon for #EUBIO22. Care to join me?

3 years ago

Another Avastin biosimilar joins the party as Roche's grip on the market loosens

3 years ago

SFJ plays hardball, demands rights to PhaseBio's lead candidate

3 years ago

As winter approaches, a European generics group raises alarm over energy prices for manufacturers

3 years ago

What more can we learn from DTC advertising? FDA's OPDP proposes new research

3 years ago

Sanofi uses creative camouflage in physician-targeted campaign for potential cancer biomarker

3 years ago

Real-time reviews for cell and gene therapies? Pfizer to FDA: Yes, please

3 years ago

Covid-19 roundup: Shionogi’s antiviral pill hits the mark; Ocugen strikes deal for intranasal vaccine

3 years ago

Wyss Institute spinout looks to revamp drug development for CNS diseases — with CRISPR tadpoles

3 years ago

TCR²'s gavo-cel survives a PhI test. Now it's head-first into PhII with a half-dozen partial responses

3 years ago

Gamida Cell prices its follow-on public offering at $20M; Rallybio touts Phase Ib data for monoclonal antibody

3 years ago

J&J debuts Kenvue as new name for $15B consumer health business spinoff

3 years ago

'Structure, beauty and clarity': With seed financing, Kaleidoscope aims to synchronize R&D teams

3 years ago

Bristol Myers got the first TYK2 approval. Frazier’s new biotech Sudo hopes to get many more

3 years ago

CMS as gatekeeper: Why lecanemab is similar but also very different from Aduhelm

3 years ago

Former Novartis drug for ultra-rare disease gets speedy FDA review

3 years ago

A new ADC biotech looks to revive secretive platform, secures Big VC backing

3 years ago

Biogen, Eisai refresh amyloid hypothesis with PhIII showing Alzheimer's med slows cognitive decline

3 years ago

New Jersey biotech nets $50M+ BARDA contract for respiratory candidate

3 years ago

Updated: Study identifies Covid-19 patients with mutations indicating remdesivir resistance

3 years ago

FDA's OTAT morphs into the Office of Therapeutic Products as new funds await

3 years ago

Updated: Does R&D spend link to final market price? Academics say 'no' in new paper

3 years ago

First page Previous page 448 449 450451452 453 454 Next page Last page